

1645

@PFDesktop\ODMA\MHODMA\iManage;335605;1  
AJC/MMY/kmb(wlm)  
08/30/02

PATENT APPLICATION  
DOCKET NO.: 0399.2012-001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


#7

Applicants: Scott K. Dessain and Richard A. Goldsby

Application No.: 09/759,984 Group Art Unit: 1645

Filed: January 12, 2001 Examiner: Not assigned

Title: PRODUCTION OF HUMAN MONOCLONAL ANTIBODIES



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202

on 8/30/02 Kathleen B. Starache

Date Signature

Kathleen B. Starache

Typed or printed name of person signing certificate

RECEIVED

SEP 05 2002

TECH CENTER 1600/2900

wrong title

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
P.O. Box 2327  
Arlington, VA 22202

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or  
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

☐ under 37 CFR 1.97(c) together with either:  
☐ a Statement under 37 CFR 1.97(e), as checked below, or  
☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:  
☐ a Statement under 37 CFR 1.97(e), as checked below, and  
☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

☐ under 37 CFR 1.97(i):  
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.  
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
  - ☒ Copies of the cited references are enclosed. (AA-AK, AA2, AL, AM, AR3-AT3)
  - ☐ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
  - ☒ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
  - ☐ The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:
    - ☐ the explanation provided on the attached sheet.
    - ☐ the explanation provided in the Specification.
    - ☐ submission of the enclosed International Search Report.
    - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
    - ☐ the enclosed English language abstract.

☐ Applicant requests that the following non-published pending applications be considered:

Examiner's  
Initials

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_\_  
Examiner

\_\_\_\_\_  
Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Anne J. Collins

Anne J. Collins, Esq.

Registration No.: 40,564

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:

August 30, 2000

PTO-1449 REPRODUCED				ATTORNEY DOCKET NO. 0399.2012-001		APPLICATION NO. 09/759,984	
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION				APPLICANT Scott K. Dessain and Richard A. Goldsby			
August 22, 2002 (Use several sheets if necessary)				FILING DATE January 12, 2001		GROUP 1645	
PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	5,629,154	05/13/97	Kim et al.	435	6	
	AB	5,639,613	06/17/97	Shay et al.	435	6	
	AC	5,645,986	07/08/97	West et al.	435	6	
	AD	5,648,215	07/15/97	West et al.	435	6	
	AE	5,686,306	11/11/97	West et al.	435	346	
	AF	5,693,474	12/02/97	Shay et al.	435	6	
	AG	5,804,380	09/08/98	Harley et al.	435	6	
	AH	5,837,453	11/17/98	Harley et al.	435	6	
	AI	5,863,726	01/26/99	Harley et al.	435	6	
	AJ	5,891,639	04/06/99	Harley et al.	435	6	
	AK	5,989,807	11/23/99	West et al.	435	6	
	AA2	6,391,554 B1	05/21/02	West et al.	435	6	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	WO 95/13383	18-MAY-95	PCT			
	AM	WO 99/35243	15-JUL-99	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AR3	Counter, C.M., et al., "Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase," <i>Oncogene</i> , 16:1217-1222, (1998).					
	AS3	Rheinwald, J.G., et al., "Properties of immortal cell lines arising from human epidermal keratinocytes stably transfected to express hTERT (human telomerase catalytic subunit)," Proceedings of the 90 <sup>th</sup> Annual Meeting of The American Association for Cancer Research, Philadelphia, PA, April 10-14, 1999.					
	AT3	Rufer, N., et al., "Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential," <i>Blood</i> , 98(3):597-603, (2001).					
EXAMINER				DATE CONSIDERED			